This year marks a decisive test for Philip Morris International (PMI)’s smoke-free ambitions in the US. The company’s goal to capture 10% of the combined cigarette and heated tobacco market by 2030 remains contingent on the Food and Drug Administration (FDA)’s approval pace.
Following a restructuring on 1st January 2026, PMI has established a dedicated US business unit. This transition signals that PMI no longer views the US as a pilot project but as a key pillar of its balance sheet.
